

Addendum to 2026 Notice of Annual General Meeting

Melbourne, Australia, 16 October 2026: 4DMedical Limited (ASX: 4DX, “4DMedical” or the “Company”) hereby gives notice to shareholders of the Company that, in relation to the Company’s Notice of Annual General Meeting dated 24 September 2026 (**Notice of Meeting**) in respect of an Annual General Meeting of Shareholders to be held 10:00am (AEDT), Wednesday, 28 October 2026 at Forum Rooms 2+3, Melbourne Connect, Mezzanine Floor, 700 Swanston Street, Carlton VIC 3053 and online via the online platform at: <https://meetings.openbriefing.com/4DX26> (**Meeting**), the Directors have determined to issue this addendum (**Addendum**) for the purposes set out below.

As announced to ASX on Wednesday, 23 September 2026, Prof Christine Jenkins has been appointed to the Board as Non-Executive Director.

As set out in the attached Addendum, *Item 12. Election of Director, Prof Christine Jenkins*, is now added to the Notice of Annual General Meeting.

In accordance with Part 1.2AA of the Corporations Act, the Company will not be dispatching physical copies of the Addendum. Instead, a copy of the Addendum will be available to view online and can be downloaded from the Company’s website at: <https://4dmedical.com/investor/investor-services/>.

Shareholders will not be sent a hard copy of the Addendum unless Shareholders have already notified the Company that they wish to receive documents such as the Addendum in hard copy. If you have any difficulty obtaining a copy of the Addendum, please contact the Company on companysecretary@4dmedical.com.

Conversely, Shareholders who receive their communications electronically will, as they have on previous occasions, receive an email from the Company’s share registry, MUFG Corporate Markets, with links directing them to the Addendum and the online voting portal.

A Replacement Proxy Form in relation to the Meeting is included with this letter. Voting on the resolutions at the Meeting is important and Shareholders who are unable to attend the Meeting in person are encouraged to exercise their voting rights by completing and returning the enclosed Replacement Proxy Form. Please refer to the full Addendum for further important information.

The Notice of Meeting and Addendum is important and should be read in its entirety. If you are in doubt as to the course of action you should follow, you should consult your financial adviser, lawyer, accountant or other professional adviser.

–ENDS–

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate

Investor Relations

investor.relations@4dmedical.com

Administration

Company Secretary

companysecretary@4dmedical.com

Media Enquiries

4Dmedia@4dmedical.com

Melbourne

Level 7 Melbourne Connect
700 Swanston Street
Carlton VIC 3053
Tel: +61 (3) 9545 5940

Los Angeles

21255 Burbank Boulevard
Suite 120
Woodland Hills CA 91367
Tel: +1 (818) 403-8490

4DMedical Limited
ABN: 31 161 684 831
Email: info@4DMedical.com
www.4DMedical.com



About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company revolutionizing respiratory care with advanced imaging and artificial intelligence. Its patented **XV Technology®** transforms standard scans into rich, functional insights that allow physicians to detect, diagnose, and monitor lung disease earlier and with greater precision.

4DMedical's expanding software portfolio includes the FDA-cleared **XV Lung Ventilation Analysis Software (XV LVAS®)**, **CT LVAS™**, and the ground-breaking **CT:VQ®** solution designed to set new benchmarks in cardiothoracic imaging by combining ventilation and perfusion analysis.

Delivered seamlessly through a Software-as-a-Service (SaaS) model, 4DMedical's solutions integrate into existing hospital infrastructure, enhancing physician productivity and enabling more personalized patient care. With the addition of advanced AI capabilities from its 2023 acquisition of **Imbio** and **contextflow** in 2026, 4DMedical continues to push the boundaries of medical imaging to redefine how respiratory disease is understood and treated worldwide.

Learn more at www.4dmedical.com



4DMEDICAL LIMITED ACN 161 684 831

ADDENDUM TO 2026 NOTICE OF ANNUAL GENERAL MEETING

4D Medical Limited (ASX: 4DX, “4D Medical” or the “Company”) hereby gives notice to shareholders of the Company that, in relation to the Company’s Notice of Annual General Meeting dated 24 September 2026 (**Notice of Meeting**) in respect of an Annual General Meeting of Shareholders to be held 10:00am (AEDT), Wednesday, 28 October 2026 at Forum Rooms 2+3, Melbourne Connect, Mezzanine Floor, 700 Swanston Street, Carlton VIC 3053 and online via the online platform at: <https://meetings.openbriefing.com/4DX26> (**Meeting**), the Directors have determined to issue this addendum (**Addendum**) for the purposes set out below.

Defined terms in the Notice of Meeting have the same meaning in this Addendum unless otherwise stated.

NEW RESOLUTION

The Notice of Meeting is amended to include an additional resolution (Item 12) as set out in this Addendum in the business to be considered at the Meeting. The additional resolution is proposed to ratify the appointment of Prof Christine Jenkins as a Director, since Prof Jenkins must not hold office (without re-election) past the Meeting in accordance with the requirements of ASX Listing Rule 14.4. The below resolution is added to the Agenda in the Notice after Item 11.

REPLACEMENT PROXY FORM

Annexed to this Addendum is a replacement Proxy Form (**Replacement Proxy Form**). To ensure clarity of voting instructions by Shareholders on the Resolutions to be considered at the Meeting, Shareholders are advised that:

- (a) If you have already completed and returned the Proxy Form annexed with the Notice of Meeting (**Original Proxy Form**) and you wish to change your original vote for Items 1 to 11 or cast votes for the additional Item 12 Resolution, **you must complete and return the Replacement Proxy Form**.
- (b) If you have already completed and returned the Original Proxy Form and **you do not wish to change your original vote for Resolutions 1 to 11 or vote on the additional Item 12 Resolution, you do not need to take any action** as the earlier submitted Original Proxy Form will be accepted by the Company for Resolutions 1 to 11 unless you submit a Replacement Proxy Form. For the sake of clarity, the Company notes that if you do not lodge a Replacement Proxy Form, you will not have cast a vote on the additional Item 12 Resolution.
- (c) If you have not yet completed and returned a Proxy Form and you wish to vote on the Resolutions in the Notice as supplemented by this Addendum, please complete and return the Replacement Proxy Form.

ENQUIRIES

Shareholders are invited to contact the Company Secretary, Hamish George at companysecretary@4dmedical.com if they have any queries in respect of the matters set out in this Addendum.

By order of the Board

Hamish George, Company Secretary

16 October 2026



SUPPLEMENTARY BUSINESS OF THE MEETING

The following additional Resolution is inserted in the Notice of Meeting as follows:

Item 12. Election of Director, Prof Christine Jenkins

To consider, and if thought fit, to pass, with or without amendment, the following resolution as an ordinary resolution:

“That, for the purposes of clause 13.1 of the Company's constitution, ASX Listing Rule 14.4, and for all other purposes, Prof Christine Jenkins, a non-executive director appointed on 23 September 2026, and being eligible, is re-elected as a director.”

SUPPLEMENTARY EXPLANATORY STATEMENT

Item 12. Election of Director, Prof Christine Jenkins

Background

The Constitution allows the Directors to appoint at any time a person to be a Director either to fill a casual vacancy or as an addition to the existing Directors, but only where the total number of Directors does not at any time exceed the maximum number specified by the Constitution.

Pursuant to the Constitution and Listing Rule 14.4, any Director so appointed holds office only until the next annual general meeting and is then eligible for election by Shareholders.

Prof Christine Jenkins, having been appointed by other Directors on 23 September 2026 in accordance with the Constitution, will retire in accordance with the Constitution and Listing Rule 14.4 and being eligible, seeks election from Shareholders pursuant to this Item 12.

If Item 12 is passed, Prof Christine Jenkins will be re-elected as a Director of the Company.

If Item 12 is not passed, Prof Christine Jenkins will not be re-elected and she will retire as a Director. The Board may consider an appointment to fill a casual vacancy pursuant to the Constitution, with ratification at the Company's next AGM.

Biography

Professor Jenkins is one of Australia's most influential figures in respiratory medicine. Over a distinguished career spanning four decades, she has combined clinical practice, research, education and policy leadership at the highest levels of the profession. She served as a senior staff specialist in respiratory medicine at Concord Hospital for 40 years, has led more than 34 clinical trials as principal investigator and authored more than 320 publications.

Her work has focused on improving diagnostic pathways and outcomes for patients with respiratory disease, particularly those presenting with breathlessness, COPD and asthma. She currently leads a Medical Research Future Fund trial developing a digital tool to assist general practitioners in assessing and managing patients with breathlessness.

Professor Jenkins has held many of the most senior leadership positions in Australian respiratory medicine, including Chair of Lung Foundation Australia, the Thoracic Society of Australia and New Zealand and the National Asthma Council. She has also played a central



role in shaping national respiratory health policy, clinical standards and patient advocacy initiatives.

She was appointed a Member of the Order of Australia for services to respiratory medicine as a clinician, administrator and educator. She is a Fellow of both the Thoracic Society of Australia and New Zealand and the Australian Academy of Health and Medical Sciences.

Directors' recommendation

Prof Christine Jenkins has a material personal interest in the outcome of Item 12 and accordingly declines to make a recommendation in respect of this Resolution.

The Board (other than Prof Christine Jenkins) considers Prof Christine Jenkins' skills and experience will continue to enhance the Board's ability to perform its role. Accordingly, the Board (with Prof Christine Jenkins abstaining) supports the election of Prof Christine Jenkins and recommends that Shareholders vote in favour of Item 12.

LODGE YOUR DIRECTION



ONLINE

<https://au.investorcentre.mpms.mufg.com>



BY MAIL

4D Medical Limited
C/- MUFG Corporate Markets (AU) Limited
Locked Bag A14
Sydney South NSW 1235 Australia



BY FAX

+61 2 9287 0309



BY HAND

MUFG Corporate Markets (AU) Limited
Parramatta Square, Level 22, Tower 6,
10 Darcy Street, Parramatta NSW 2150

*During business hours Monday to Friday



ALL ENQUIRIES TO

Telephone: +61 1300 554 474

LODGE A PROXY FORM

This Voting Form (and any Power of Attorney under which it is signed) must be received at an address given above by **10:00am (AEDT) on Monday, 26 October 2026**, being not later than 48 hours before the commencement of the Meeting. Any Voting Form received after that time will not be valid for the scheduled Meeting.

Voting Forms may be lodged using the reply paid envelope or:



ONLINE

<https://au.investorcentre.mpms.mufg.com>

Login to the Investor Centre website using the holding details as shown on the Voting Form. Select 'Voting' and follow the prompts to lodge your vote. To use the online lodgement facility, shareholders will need their "Holder Identifier" - Securityholder Reference Number (SRN) or Holder Identification Number (HIN).



BY MOBILE DEVICE

Our voting website is designed specifically for voting online. You can now lodge your vote by scanning the QR code adjacent or enter the voting link <https://au.investorcentre.mpms.mufg.com> into your mobile device. Log in using the Holder Identifier and postcode for your shareholding.

To scan the code you will need a QR code reader application which can be downloaded for free on your mobile device.

QR Code



HOW TO COMPLETE THIS SHAREHOLDER PROXY FORM

YOUR NAME AND ADDRESS

This is your name and address as it appears on the Company's share register. If this information is incorrect, please make the correction on the form. Shareholders sponsored by a broker should advise their broker of any changes. **Please note: you cannot change ownership of your shares using this form.**

APPOINTMENT OF PROXY

If you wish to appoint the Chairman of the Meeting as your proxy, mark the box in Step 1. If you wish to appoint someone other than the Chairman of the Meeting as your proxy, please write the name and email of that individual or body corporate in Step 1. A proxy need not be a shareholder of the Company.

DEFAULT TO CHAIRMAN OF THE MEETING

Any directed proxies that are not voted on a poll at the Meeting will default to the Chairman of the Meeting, who is required to vote those proxies as directed. Any undirected proxies that default to the Chairman of the Meeting will be voted according to the instructions set out in this Proxy Form, including where the Items are connected directly or indirectly with the remuneration of KMP.

VOTES ON ITEMS OF BUSINESS – PROXY APPOINTMENT

You may direct your proxy how to vote by placing a mark in one of the boxes opposite each item of business. All your shares will be voted in accordance with such a direction unless you indicate only a portion of voting rights are to be voted on any item by inserting the percentage or number of shares you wish to vote in the appropriate box or boxes. If you do not mark any of the boxes on the items of business, your proxy may vote as they choose. If you mark more than one box on an item your vote on that item will be invalid.

APPOINTMENT OF A SECOND PROXY

You are entitled to appoint up to two persons as proxies to attend the Meeting and vote on a poll. If you wish to appoint a second proxy, an additional Proxy Form may be obtained by telephoning the Company's share registry or you may copy this form and return them both together.

To appoint a second proxy you must:

- on each of the first Proxy Form and the second Proxy Form state the percentage of your voting rights or number of shares applicable to that form. If the appointments do not specify the percentage or number of votes that each proxy may exercise, each proxy may exercise half your votes. Fractions of votes will be disregarded; and
- return both forms together.

SIGNING INSTRUCTIONS

You must sign this form as follows in the spaces provided:

Individual: where the holding is in one name, the holder must sign.

Joint Holding: where the holding is in more than one name, either shareholder may sign.

Power of Attorney: to sign under Power of Attorney, you must lodge the Power of Attorney with the registry. If you have not previously lodged this document for notation, please attach a certified photocopy of the Power of Attorney to this form when you return it.

Companies: where the company has a Sole Director who is also the Sole Company Secretary, this form must be signed by that person. If the company (pursuant to section 204A of the *Corporations Act 2001*) does not have a Company Secretary, a Sole Director can also sign alone. Otherwise this form must be signed by a Director jointly with either another Director or a Company Secretary. Please indicate the office held by signing in the appropriate place.

CORPORATE REPRESENTATIVES

If a representative of the corporation is to attend the Meeting the appropriate "Certificate of Appointment of Corporate Representative" must be received at support@cm.mpms.mufg.com prior to admission in accordance with the Notice of Annual General Meeting. A form of the certificate may be obtained from the Company's share registry or online at www.mpms.mufg.com/en/mufg-corporate-markets.

NAME SURNAME
ADDRESS LINE 1
ADDRESS LINE 2
ADDRESS LINE 3
ADDRESS LINE 4
ADDRESS LINE 5
ADDRESS LINE 6



X99999999999

PROXY FORM

I/We being a member(s) of 4DMedical Limited and entitled to attend and vote hereby appoint:

APPOINT A PROXY

☐ the Chairman of the Meeting (mark box)

OR if you are **NOT** appointing the Chairman of the Meeting as your proxy, please write the name and email of the person or body corporate you are appointing as your proxy. An email will be sent to your appointed proxy with details on how to access the virtual meeting.

Name

Email

or failing the person or body corporate named, or if no person or body corporate is named, the Chairman of the Meeting, as my/our proxy to act on my/our behalf (including to vote in accordance with the following directions or, if no directions have been given and to the extent permitted by the law, as the proxy sees fit) at the Annual General Meeting of the Company to be held at **10:00am (AEDT) on Wednesday, 28 October 2026 (the Meeting)** and at any postponement or adjournment of the Meeting.

The Meeting will be conducted as a hybrid event. You can participate by attending in person at **Forum Room 2+3, Melbourne Connect, Mezzanine Floor, 700 Swanston Street, Carlton VIC 3053** or logging in online at <https://meetings.openbriefing.com/4DX26> (refer to details in the Virtual Meeting Online Guide).

Important for Items 2; 4a – 7 inclusive and 10: If the Chairman of the Meeting is your proxy, either by appointment or by default, and you have not indicated your voting intention below, you expressly authorise the Chairman of the Meeting to exercise the proxy in respect of Items 2; 4a – 7 inclusive and 10, even though the Items are connected directly or indirectly with the remuneration of a member of the Company's Key Management Personnel (KMP).

The Chairman of the Meeting intends to vote undirected proxies in favour all items of business.

VOTING DIRECTIONS

Proxies will only be valid and accepted by the Company if they are signed and received no later than 48 hours before the Meeting.

Please read the voting instructions overleaf before marking any boxes with an ☒.

Resolutions

	For	Against	Abstain*		For	Against	Abstain*
2 Remuneration Report	☐	☐	☐	9 Ratification of prior issue of shares	☐	☐	☐
3 Re-election of Dr Geraldine McGinty as a Director	☐	☐	☐	10 Non-Executive Directors' Fees	☐	☐	☐
4a Approval for the proposed issue of Options to Director – Mr John Livingston	☐	☐	☐	11 Amendment to Constitution	☐	☐	☐
4b Approval for the proposed issue of Restricted Stock Units to Director – Dr Robert A. Figlin	☐	☐	☐	12 Election of Prof Christine Jenkins as a Director	☐	☐	☐
4c Approval for the proposed issue of Restricted Stock Units to Director – Dr Geraldine McGinty	☐	☐	☐				
5 Issue of RSUs and Options to the Managing Director and CEO	☐	☐	☐				
6 Issue of Options to the Executive Director and CFO	☐	☐	☐				
7 Renewal of approval for the Incentive Plan	☐	☐	☐				
8 Approval for the proposed issue of the Contextflow Options	☐	☐	☐				



* If you mark the Abstain box for a particular Item, you are directing your proxy not to vote on your behalf on a show of hands or on a poll and your votes will not be counted in computing the required majority on a poll.

SIGNATURE OF SHAREHOLDERS – THIS MUST BE COMPLETED

Shareholder 1 (Individual)

Sole Director and Sole Company Secretary

Joint Shareholder 2 (Individual)

Director/Company Secretary (Delete one)

Joint Shareholder 3 (Individual)

Director

This form should be signed by the shareholder. If a joint holding, either shareholder may sign. If signed by the shareholder's attorney, the power of attorney must have been previously noted by the registry or a certified copy attached to this form. If executed by a company, the form must be executed in accordance with the company's constitution and the *Corporations Act 2001* (Cth).

4DX PRX2601N